Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from MDxHealth ( (MDXH) ) is now available.
On August 5, 2025, MDxHealth SA announced its preliminary financial results for the second quarter of 2025, highlighting a 20% year-over-year revenue increase to $26.6 million and achieving a positive adjusted EBITDA of $1.4 million. The company also revealed a definitive agreement to acquire the Exosome Diagnostics business from Bio-Techne for $15 million, which is expected to accelerate revenue growth and enhance its leadership in prostate cancer diagnostics. This strategic acquisition is anticipated to contribute significantly to MDxHealth’s revenue and adjusted EBITDA starting in the fourth quarter of 2025.
The most recent analyst rating on (MDXH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s stock reflects strong technical momentum and positive earnings call insights, but financial instability and unattractive valuation weigh heavily on the score.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA is a leading precision diagnostics company specializing in tissue-based and liquid-based diagnostic tests, with a strong focus on urology and prostate cancer diagnostics. The company’s primary products include the GPS and Confirm mdx tests, and it is expanding its capabilities in prostate cancer diagnostics with the acquisition of the ExoDx Prostate test.
Average Trading Volume: 72,427
Technical Sentiment Signal: Sell
Current Market Cap: $120.3M
For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.